Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?

Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T cells may exert multiple pro-inflammatory actions, but also possess regulatory fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasileiadis, Georgios K., Dardiotis, Efthymios, Mavropoulos, Athanasios, Tsouris, Zisis, Tsimourtou, Vana, Bogdanos, Dimitrios P., Sakkas, Lazaros I., Hadjigeorgiou, Georgios M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230324/
https://www.ncbi.nlm.nih.gov/pubmed/30415321
http://dx.doi.org/10.1007/s13317-018-0109-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230324/
https://www.ncbi.nlm.nih.gov/pubmed/30415321
http://dx.doi.org/10.1007/s13317-018-0109-x

Ejemplares similares